A securities class action has been filed in the USDC – S.D.IN. against Telix Pharmaceuticals Limited (TLX) (“Telix” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Telix securities publicly traded on the NASDAQ  between February 21, 2025, and August 28, 2025, both dates inclusive (the “Class Period”).

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies.

The complaint alleges defendants made false and/or misleading statements and/or failed to disclose that:

(1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates;

(2) Defendants materially overstated the quality of Telix’s supply chain and partners; and

(3) as a result, Defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times, thereby harming investors.

If you purchased Telix securities publicly traded on the NASDAQ  during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.